Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    Cenobamate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,188Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Angelini Sanctioned After Speaker Blasts 'Stupid' EMA
    Angelini Sanctioned After Speaker Blasts 'Stupid' EMA

    25 Nov 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/marketing/angelini-faces-watchdogs-wrath-after-speaker-blasts-stupid-ema

    FIERCE PHARMA
    25 Nov 2025
    Share Share
    SK Life Science Reveal C035 Study Analyses In Epilepsia & Seizure
    SK Life Science Reveal C035 Study Analyses In Epilepsia & Seizure

    17 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sk-life-science-inc-announces-publication-of-c035-study-analyses-in-epilepsia-and-seizure-302616095.html

    PR NEWSWIRE
    17 Nov 2025
    Share Share
    SK Eyes Xcopri Expansion with Phase 3 Win in New Seizure Type
    SK Eyes Xcopri Expansion with Phase 3 Win in New Seizure Type

    17 Sep 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/sks-blockbuster-hopeful-xcopri-reduces-seizures-phase-3-trial-teeing-fda-expansion-bid

    FIERCE PHARMA
    17 Sep 2025
    Share Share
    SK Eyes Xcopri Expansion with Ph 3 Win in New Seizure Type
    SK Eyes Xcopri Expansion with Ph 3 Win in New Seizure Type

    17 Sep 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/sks-blockbuster-hopeful-xcopri-reduces-seizures-phase-3-trial-teeing-fda-expansion-bid

    FIERCE PHARMA
    17 Sep 2025
    Share Share
    SK Life Science Launches Second National Ad for Anti-Seizure Drug
    SK Life Science Launches Second National Ad for Anti-Seizure Drug

    19 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sk-life-science-launches-its-second-national-ad-continuing-to-lead-with-the-only-direct-to-consumer-commercial-for-an-anti-seizure-drug-in-the-us-302458054.html

    PR NEWSWIRE
    19 May 2025
    Share Share
    SK Life Science to Present Xcopri CV Data at AAN Annual Meeting
    SK Life Science to Present Xcopri CV Data at AAN Annual Meeting

    04 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sk-life-science-inc-to-showcase-important-xcopri-cenobamate-tablets-cv-data-on-responsive-neurostimulation-epileptiform-events-at-the-77th-american-academy-of-neurology-aan-annual-meeting-302420275.html

    PR NEWSWIRE
    04 Apr 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.